Should I buy or sell Esperion Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks .

What is Esperion Therapeutics' stock price target for 2024?

5 brokerages have issued 12 month target prices for Esperion Therapeutics' stock. Their ESPR share price targets range from $4.00 to $16.00. On average, they expect the company's share price to reach $9.33 in the next twelve months. This suggests a possible upside of 399.1% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts .

How have ESPR shares performed in 2024?

Esperion Therapeutics' stock was trading at $2.99 at the start of the year. Since then, ESPR stock has decreased by 37.5% and is now trading at $1.87. View the best growth stocks for 2024 here .

Are investors shorting Esperion Therapeutics?

Esperion Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 19,920,000 shares, an increase of 12.7% from the March 15th total of 17,670,000 shares. Based on an average trading volume of 6,710,000 shares, the days-to-cover ratio is currently 3.0 days. Currently, 11.8% of the company's stock are short sold. View Esperion Therapeutics' Short Interest .

When is Esperion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ESPR earnings forecast .

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.03. The biopharmaceutical company earned $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the business posted ($0.76) EPS.

What ETFs hold Esperion Therapeutics' stock?

ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include Jacob Forward ETF (JFWD) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com . Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW) , Targa Resources (TRGP) , Navios Maritime Partners (NMM) , NVIDIA (nvda) , Micron Technology (MU) , SFL (SFL) , Gilead Sciences (GILD) , Boeing (BA) , Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn) .

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Capital Advisors Wealth Management LLC (0.01%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech. View institutional ownership trends .

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ESPR

Esperion Therapeutics (ESPR) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ESPR Stock Alerts

$1.87

+0.03 (+1.63%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.81
▼
$2.03
50-Day Range: $1.84
▼
$3.24
52-Week Range: $0.70
▼
$3.40

Volume: 6.02 million shs
Average Volume: 6.80 million shs
Market Capitalization: $354.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.33

Get Esperion Therapeutics alerts:

Esperion Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 399.1% Upside
$9.33 Price Target
Short Interest: Bearish
11.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.76
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.68) to $0.31 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

323rd out of 918 stocks

Pharmaceutical Preparations Industry

134th out of 402 stocks

3.2

Analyst's Opinion

Consensus Rating
Esperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Esperion Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.82% of the float of Esperion Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Esperion Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Esperion Therapeutics has recently increased by 12.73%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Esperion Therapeutics does not currently pay a dividend.
Dividend Growth
Esperion Therapeutics does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Esperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.
Environmental Sustainability
The Environmental Impact score for Esperion Therapeutics is -2.76.

1.1

News and Social Media Coverage

Search Interest
77 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 185% compared to the previous 30 days.
MarketBeat Follows
35 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 218% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.60% of the stock of Esperion Therapeutics is held by insiders.
Percentage Held by Institutions
47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.68) to $0.31 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Esperion Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Esperion Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Esperion Therapeutics Stock (NASDAQ:ESPR)

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

ESPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ESPR Stock News Headlines

April 11, 2024 | americanbankingnews.com

Esperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at Needham & Company LLC

April 8, 2024 | msn.com

Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 7, 2024 | globenewswire.com

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

April 3, 2024 | msn.com

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday

April 1, 2024 | globenewswire.com

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

March 26, 2024 | finance.yahoo.com

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

March 26, 2024 | msn.com

Why Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2024 | globenewswire.com

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

March 25, 2024 | msn.com

Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session

March 23, 2024 | money.usnews.com

Esperion Therapeutics Inc.

March 22, 2024 | finance.yahoo.com

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

March 22, 2024 | businesswire.com

U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

March 22, 2024 | globenewswire.com

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

March 22, 2024 | marketwatch.com

Esperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medications

March 22, 2024 | globenewswire.com

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

March 14, 2024 | msn.com

Terns to report Phase 1 data on GLP-1 drug in 2H 2024

March 4, 2024 | finance.yahoo.com

11 Best Small Cap Pharma Stocks to Invest In

February 28, 2024 | seekingalpha.com

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

February 28, 2024 | finance.yahoo.com

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

Q4 2023 Esperion Therapeutics Inc Earnings Call

February 27, 2024 | seekingalpha.com

Esperion Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 27, 2024 | finanznachrichten.de

Esperion Therapeutics, Inc.: Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024 | finance.yahoo.com

Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023

February 27, 2024 | globenewswire.com

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024 | finance.yahoo.com

12 Best Medical Stocks to Buy Under $10

See More Headlines

Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ESPR
CUSIP: N/A
CIK: 1434868
Web: www.esperion.com
Phone: (734) 887-3903
Fax: N/A
Employees: 240
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.33
High Stock Price Target: $16.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +399.1%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-209,250,000.00
Net Margins: -179.87%
Pretax Margin: -179.87%
Return on Equity: N/A
Return on Assets: -91.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.29
Quick Ratio: 0.87

Sales & Book Value

Annual Sales: $116.33 million
Price / Sales: 3.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.85) per share
Price / Book: -0.49

Miscellaneous

Outstanding Shares: 189,400,000
Free Float: 188,265,000
Market Cap: $354.18 million
Optionable: Optionable
Beta: 0.84

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Sheldon L. Koenig (Age 58)
President, CEO & Director
Comp: $1.2M
Mr. Benjamin O. Looker (Age 42)
General Counsel
Comp: $550.35k
Dr. JoAnne Micale Foody FACC (Age 58)
M.D., Chief Medical Officer
Comp: $771.19k
Mr. Benjamin Halladay M.B.A. (Age 38)
Chief Financial Officer
Mr. Glenn P. Brame (Age 66)
Chief Technical Operations Officer
Tiffany Aldrich M.B.A.
Associate Director of Corporate Communications
Ms. Betty Jean Swartz
Chief Business Officer
Mr. Eric J. Warren R.Ph. (Age 52)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ESPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View ESPR analyst ratings or view top-rated stocks.
What is Esperion Therapeutics' stock price target for 2024?: 5 brokerages have issued 12 month target prices for Esperion Therapeutics' stock. Their ESPR share price targets range from $4.00 to $16.00. On average, they expect the company's share price to reach $9.33 in the next twelve months. This suggests a possible upside of 399.1% from the stock's current price.
View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts.
How have ESPR shares performed in 2024?: Esperion Therapeutics' stock was trading at $2.99 at the start of the year. Since then, ESPR stock has decreased by 37.5% and is now trading at $1.87.
View the best growth stocks for 2024 here.
Are investors shorting Esperion Therapeutics?: Esperion Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 19,920,000 shares, an increase of 12.7% from the March 15th total of 17,670,000 shares. Based on an average trading volume of 6,710,000 shares, the days-to-cover ratio is currently 3.0 days. Currently, 11.8% of the company's stock are short sold.
View Esperion Therapeutics' Short Interest.
When is Esperion Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ESPR earnings forecast.
How were Esperion Therapeutics' earnings last quarter?: Esperion Therapeutics, Inc. (NASDAQ:ESPR) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.03. The biopharmaceutical company earned $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the business posted ($0.76) EPS.

What ETFs hold Esperion Therapeutics' stock?: ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include Jacob Forward ETF (JFWD).Invesco Nasdaq Future Gen 200 ETF (QQQS).
What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?: 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.
What other stocks do shareholders of Esperion Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).
Who are Esperion Therapeutics' major shareholders?: Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Capital Advisors Wealth Management LLC (0.01%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech.
View institutional ownership trends.
How do I buy shares of Esperion Therapeutics?: Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ESPR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial